Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation

Diabetes, Obesity and Metabolism

Volumn 3, Issue 4, 2001, Pages 287-292

  Dmitrewski, J ^a   Krentz, A J ^b,c   Mayer, A D ^a   Buckels, J A C ^a   Barnes, A D ^a   Smith, J ^b   Nattrass, M ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b SELLY OAK HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alanine; Blood glucose; Cyclosporin (CyA); Immunosuppression; Insulin; Intermediary metabolism; Renal transplantation; Tacrolimus (FK506)

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; ALANINE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; BIOLOGICAL MARKER; C PEPTIDE; CARBOHYDRATE; CREATININE; CYCLOSPORIN; FATTY ACID; GLUCOSE; GLYCEROL; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN; IMMUNOSUPPRESSIVE AGENT; KETONE BODY; LACTIC ACID; METHYLPREDNISOLONE; PERCHLORIC ACID; PYRUVIC ACID; SODIUM CHLORIDE; STEROID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HORMONE ACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; MALE; METABOLIC REGULATION; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0034844168     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00132.x     Document Type: Article

References (24)

1. An analysis of cyclosporine efficacy and toxicity after liver transplantation
2. The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients
3. Posttransplant hyperglycemia: Increased incidence in cyclosporine-treated renal allograft recipients
4. FK506 for liver, kidney and pancreas transplantation
5. New onset of diabetes in FK506 vs cyclosporine-treated kidney transplant recipients
6. Long-term insulin requirement after liver transplantation with FK506 in American veterans
7. Causes of renal allograft loss: Progress in the 1980s, challenges for the 1990s
8. Medical progress: Renal transplantation
9. FK506 versus cyclosporin in the prevention of renal allograft rejection. European pilot study: Six-week results
10. Optimized methods to measure aceto-acetate, 3-hydroxybutyrate, glycerol, alanine, pyruvate, lactate and glucose in human blood using a centrifugal analyser with a fluorimetric attachment
11. Blood intermediary metabolite and insulin concentrations after an overnight fast: Reference ranges for adults and inter-relations
12. Metabolic effects of cyclosporin A and FK506 in liver transplant recipients
13. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment
14. FK506 in experimental renal allografts
15. Synthesis-secretion coupling of insulin: Effect of cyclosporin
16. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans
17. Renal disease, insulin resistance and glucose intolerance
18. The limitations to and valid use of C-peptide as a marker of the secretion of insulin
19. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM
20. Impaired glucose tolerance is characterized by multiple abnormalities in the regulation of intermediary metabolism
21. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials
22. Insulin resistance: Implications for type II diabetes mellitus and coronary heart disease